EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy

Coralien H Vink, Jack F M Wetzels, Anne-Els van de Logt

Kidney International Reports · 2024-12 · 9 (12) · 3439-3445

DOI: 10.1016/j.ekir.2024.08.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International Reports, 2024-12. Verfasst von Coralien H Vink und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Radboud institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Standard treatment with cyclophosphamide (CP) or rituximab (RTX) is suboptimal. We adapted and used the low-dose regimen used in vasculitis (RTX 2 × 1000 mg, CP 1.5 mg/kg/d × 8 weeks, and prednisone [i.v. 2 × 1 g + 3 weeks oral starting at 1 mg/kg]).

Methods

High-risk, anti-PLA2R antibodies (PLA2Rab)-positive patients with membranous nephropathy (MN) were included in this single-arm prospective cohort study. PLA2Rab levels were regularly measured. We report the PLA2Rab kinetics and overall immunological and clinical remission (CR) rate.

Results

We analyzed 26 patients (15 males, aged 57 ± 14 years, PLA2Rab titer 176 [115-460] RU/ml, serum creatinine 128 [102-136] μmol/l, serum albumin 18 [14-21] g/l, and urinary protein-to-creatinine ratio [uPCR] 7.1 [5.7-10] g/10 mmol). Within 8 weeks immunological remission (IR) (enzyme-linked immunosorbent assay 7 days. Serious adverse events occurred in 4 patients. Adverse events were mild; leukopenia was most frequent.

Conclusion

Low-dose triple therapy induced a rapid IR and CR in most patients. Patients with insufficient clinical response were characterized by high baseline PLA2Rab levels and longer PLA2Rab T1/2. Assessment of PLA2Rab levels within 2 to 4 weeks after start of therapy may enable to identify patients who need more intensive therapy.

Schlagwörter

Stichwörter der Autor:innen

anti-PLA2R antibodiesimmunosuppressionmembranous nephropathy

Autor:innen und Institutionen

  • Department of Nephrology, Radboud institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.

Zitieren

APA

Vink, C. H., Wetzels, J. F. M., & Logt, A. V. (2024). Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy. Kidney International Reports, 9(12), 3439-3445. https://doi.org/10.1016/j.ekir.2024.08.033

Vancouver

Vink CH, Wetzels JFM, Logt AV. Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy. Kidney International Reports. 2024;9(12):3439-3445. doi:10.1016/j.ekir.2024.08.033

BibTeX
@article{Vink2024,
  author = {Vink, Coralien H and Wetzels, Jack F M and Logt, Anne-Els van de},
  title = {Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy},
  journal = {Kidney International Reports},
  year = {2024},
  volume = {9},
  number = {12},
  pages = {3439--3445},
  doi = {10.1016/j.ekir.2024.08.033}
}
Kostenlos starten →